For decades, leukemia and lymphoma were treated with one main approach: chemotherapy. It was harsh, often ineffective for advanced cases, and left patients weakened for months. But today, something entirely new is happening. Targeted therapy and cellular therapy aren’t just new options-they’re rewriting the rules of what’s possible for blood cancers.
Imagine a treatment that doesn’t just attack all fast-growing cells, but zeroes in on the exact molecular flaw that makes a cancer cell tick. That’s targeted therapy. Or picture a treatment that takes your own immune cells, reprograms them in a lab to hunt down cancer, and puts them back into your body like living missiles. That’s CAR T-cell therapy. Both are changing survival rates, reducing side effects, and giving people with once-deadly diagnoses a real shot at long-term remission-or even cure.
How Targeted Therapies Work: Precision Over Brute Force
Traditional chemo works like a bomb-it kills anything that divides quickly, cancer or not. Targeted therapies are more like a lockpick. They block specific proteins or pathways that cancer cells depend on to survive.
Take chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Before targeted drugs, patients often faced years of repeated chemo cycles with little long-term gain. Now, drugs like ibrutinib (a BTK inhibitor that blocks a key signaling protein in B-cells) and venetoclax (a BCL-2 inhibitor that triggers cancer cell death) are used in combination. These are taken as pills, daily, often for months or years. No hospital stays. No constant nausea. No hair loss.
The results? A 2025 study from the CLL Society found that patients on targeted therapies lived nearly twice as long without disease progression compared to those on old-school chemo. The time between diagnosis and a dangerous complication called Richter transformation jumped from 2.2 years to 4.9 years. That’s not just a delay-it’s a fundamental shift in how the disease behaves.
But targeted drugs aren’t perfect. Cancer cells evolve. A patient might respond for three years, then relapse. That’s especially true for those with mutations in the TP53 gene, which makes the cancer more stubborn. And while these drugs are far gentler than chemo, they still come with risks: bleeding, high blood pressure, irregular heart rhythms, and infections.
Cellular Therapy: Turning Your Immune System Into a Weapon
If targeted therapy is a scalpel, CAR T-cell therapy is a full-scale biological upgrade.
The process starts with a simple blood draw-leukapheresis. Your T cells, the body’s natural assassins, are pulled out. Then, in a lab, scientists add a gene that makes them recognize CD19, a protein found on the surface of most B-cell lymphomas and leukemias. These modified cells are multiplied, sometimes into the billions. Then, they’re infused back into you.
It’s not magic. It’s science. And it’s working.
One 2025 study in the Journal of Clinical Oncology looked at 23 patients with mantle cell lymphoma who had tried everything else. After a single infusion of LV20.19 CAR T-cells, every single one responded. Eighty-eight percent went into complete remission. That’s unheard of in relapsed disease.
Two major CAR T-cell products dominate the market: Yescarta (axicabtagene ciloleucel, made by Kite/Gilead) and Kymriah (tisagenlecleucel, by Novartis). Both target CD19. But newer versions are already in development. Kite’s KITE-363 and KITE-753 now target both CD19 and CD20-two different cancer markers-to prevent the cancer from slipping away by hiding one antigen.
The downside? Toxicity. Within days of infusion, up to 40% of patients experience cytokine release syndrome (CRS)-a flood of immune chemicals that can spike fever, drop blood pressure, and require ICU care. Neurotoxicity is also common: confusion, seizures, trouble speaking. These are serious, but manageable in centers with experience.
And then there’s cost. A single CAR T-cell treatment runs between $373,000 and $475,000. That’s not just a financial burden-it creates ethical dilemmas. Can we justify this for a 78-year-old with heart disease? Who pays when insurance denies coverage? These aren’t theoretical questions-they’re daily realities in clinics.
Comparing the Two: When to Use What
There’s no one-size-fits-all. The choice depends on the cancer type, stage, prior treatments, and patient health.
| Feature | Targeted Therapy (e.g., Ibrutinib, Venetoclax) | Cellular Therapy (e.g., Yescarta, Kymriah) |
|---|---|---|
| Administration | Oral pill, daily | Single IV infusion |
| Time to Treatment | Days to start | 3-5 weeks (manufacturing delay) |
| Duration of Effect | Continuous (lifelong for many) | Potentially permanent |
| Primary Toxicity | Bleeding, hypertension, infection | Cytokine release syndrome, neurotoxicity |
| Best For | Early relapse, elderly, outpatient care | Multi-refractory disease, young patients with aggressive lymphoma |
| Cost (2025) | $15,000-$25,000/month | $373,000-$475,000 per course |
For a 65-year-old with newly diagnosed CLL, starting with venetoclax plus obinutuzumab might mean 3-5 years of disease control without chemo. For a 30-year-old with relapsed diffuse large B-cell lymphoma who’s tried two rounds of chemo? CAR T-cell therapy could be the only path to long-term survival.
The Real-World Challenges: Access, Infrastructure, and Equity
These therapies aren’t available everywhere. CAR T-cell therapy requires a certified center with ICU beds, specialized nursing staff, and 24/7 access to toxicology experts. In the U.S., 89% of NCI-designated cancer centers offer it. But in community hospitals? Only 32% do.
Manufacturing is another bottleneck. It takes 3-5 weeks to grow a patient’s CAR T-cells. During that time, the cancer can grow. Some patients die waiting. Newer approaches-like off-the-shelf CAR T-cells from donor cells-are in trials and could change this. But they’re not here yet.
And what about the patients who don’t respond? Some develop resistance to both BTK and BCL-2 inhibitors. These “double-refractory” patients are the hardest to treat. Right now, CAR T-cell therapy is often their last hope. But even then, not all respond. Researchers are now testing next-gen therapies: dual-target CARs, CARs with built-in safety switches, and even CARs that work without needing to be genetically modified.
What’s Next? The Future Is Already Here
The FDA just gave priority review to liso-cel (lisocabtagene maraleucel) for marginal zone lymphoma-approval expected by December 2025. That’s one more disease added to the list of treatable cancers.
Experts predict that by 2030, CAR T-cell therapy will move from last-resort to first-line treatment for high-risk lymphomas. Imagine a patient diagnosed with aggressive B-cell lymphoma-instead of chemo, they get CAR T-cells immediately. Early data from ASH 2025 suggest this could be possible.
Meanwhile, targeted therapies are getting smarter. New BTK inhibitors like pirtobrutinib work even in patients who’ve become resistant to older ones. Combination regimens are shortening treatment duration. Instead of lifelong pills, some patients may now get 12-18 months of therapy and then stop.
The big question isn’t whether these therapies work. It’s how we use them wisely. Who gets them? When? And at what cost? We’re no longer choosing between cure and palliation. We’re choosing between multiple powerful options-and that’s a new kind of challenge for doctors and patients alike.
Real Outcomes, Real Lives
One patient in Brisbane, diagnosed with mantle cell lymphoma in 2023, tried two chemo regimens. Both failed. He was told his life expectancy was under a year. He received Yescarta in early 2025. His cancer vanished. Two years later, he’s back hiking, working part-time, and playing with his grandkids. No chemo. No hospital. Just a single infusion-and a second chance.
Another, a 71-year-old with CLL, started on ibrutinib and venetoclax. After 18 months, his minimal residual disease (MRD) was undetectable. His oncologist says he’s in a functional cure. He’s off all drugs now, monitored every six months.
These aren’t outliers. They’re becoming the new normal.
Are targeted therapies better than chemotherapy for leukemia and lymphoma?
Yes, for most patients today. Targeted therapies like BTK and BCL-2 inhibitors have fewer side effects than chemo, don’t require hospitalization, and often lead to longer remissions. They’re now the first choice for many types of CLL and lymphoma. But they’re not always curative-some patients still need CAR T-cell therapy or transplant if they relapse.
How long does CAR T-cell therapy take from start to finish?
The entire process takes about 6-8 weeks. First, your T cells are collected (1-2 days). Then, they’re sent to a lab to be modified and multiplied-this takes 3-5 weeks. After that, you have a short chemo prep (5-7 days) to make room for the new cells, then the infusion. Recovery from side effects like CRS or neurotoxicity can take another 2-4 weeks. Some patients are discharged after 3-4 weeks total.
Can you get CAR T-cell therapy more than once?
It’s rare, but possible. Most patients who relapse after CAR T-cell therapy don’t get a second infusion because the cancer often escapes by losing the target (like CD19). Newer therapies targeting multiple antigens (CD19 and CD20) are designed to prevent this. Some clinical trials are testing second CAR T-cell infusions with different targets, but this isn’t standard yet.
Why are these therapies so expensive?
CAR T-cell therapy is expensive because it’s personalized medicine. Each dose is made from one patient’s cells, in a complex, labor-intensive process. The lab work, quality control, logistics, and specialized care required add up. Targeted drugs are costly too-manufacturing precision molecules and running long-term trials drives prices up. Insurance covers most of it, but out-of-pocket costs can still hit $15,000-$25,000 per month for targeted therapies.
Are there side effects years after CAR T-cell therapy?
Yes. Some patients develop long-term low blood counts, increased risk of infections, or neurological issues like memory problems. There’s also a small risk of secondary cancers, though this is rare. Regular follow-up with a hematologist is essential. The good news? Most patients who survive the first year after CAR T-cell therapy have excellent long-term quality of life.
Final Thoughts
Leukemia and lymphoma are no longer the death sentences they once were. We’re in a new era-one where a pill or a single infusion can change a patient’s life. The tools are here. The science is proven. The challenge now is making them accessible, affordable, and used wisely. For patients, that means asking questions: What’s my goal? What are the risks? What comes next? For doctors, it means choosing the right path, not just the newest one. And for the system? It means catching up to the science before the gap between hope and access becomes too wide to cross.
Write a comment